Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akela Pharma has announced that as previously requested by the FDA, it has started over again the required inhalation toxicology studies.
Subscribe to our email newsletter
The studies performed at US based CRO are expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl Taifun Phase III clinical trial in patients in the second quarter of 2009.
Halvor Jaeger, CEO of Akela Pharma, said: “We are still on track to deliver the required toxicology studies results in time to allow us to meet our previously disclosed regulatory submission timelines of Q1-2010 for the EU and Q3-2010 for the US.”